Hoag First Hospital in Orange County to Enroll Patients in NK Cell Therapy Clinical Trial for Triple-Negative Breast Cancer Patients


2021-10-16 02:00:05 BioSpace


 Hoag Presbyterian Memorial Hospital today announced that it has enrolled its first two patients in a clinical study evaluating "Natural Killer," or NK, cell therapy in women with triple-negative breast cancer. Hoag is the first and only site in Orange County enrolling patients in the study. The phase1/b2 open-label study will evaluate the safety and efficacy of a combination of chemo-immunotherapy with "Trodelvy," a low dose chemotherapy, in combination with Culver City, Calif.-based ImmunityBio's Anktiva receptor agonist, and NK cell therapy, a type of immunotherapy. Participants are triple negative breast cancer patients who have at least two prior treatments for metastatic disease. Treatment will continue for up to one year.   Cell therapy involves modifying immune cells to recognize – and kill – cancer. Hoag is involved in a variety of cell therapy trials evaluating "natural killer," or NK cell therapy, which has proven to be beneficial in treating solid tumors. "Metastatic triple negative breast cancer patients often have a poor prognosis and high cancer recurrence rates and short duration of responses with current therapy at an unacceptable high level of toxicity," said Chaitali Nangia, M.D., Co-Director, NK Cell Therapy Research at Hoag Family Cancer Institute and principal investigator for the trial. "We are at the frontier of these novel combinatorial approaches with the use of 'Natural Killer' cells, which have the potential to work together with other agents to give durable and deep responses while maintaining patients' quality of life." Triple-negative breast cancer accounts for about 10-15% of all breast cancers, according to the American Cancer Society. Triple-negative breast cancer is more common among women under the age of 40, black women and those with the BRCA1 mutation. Triple negative breast cancers are a more aggressive form of breast cancer and until recently have lacked specific targets for personalized therapy. Combinatorial chemo immunotherapeutics have started to fill those gaps and are now the backbone of a number of clinical trials designed to target these pathways. "Hoag is committed to leading the way in advancing treatment options and improving health care by exploring the safety and efficacy of new drugs and therapies, including the promising area of immunotherapy and, in particular, evaluating the efficacy of NK cells in treating several types of challenging cancer," said Burton Eisenberg, M.D., Grace E. Hoag Executive Medical Director Endowed Chair, Hoag Family Cancer Institute. Hoag's clinical trials are heavily supported by philanthrophy, which provides the infrastructure to attract and support these advanced trials, including research nurses, data and trial coordinators, variant scientists and more. Hoag Family Cancer Institute offers comprehensive clinical trials for all solid tumor cancers. For more information, email clinicalresearch@hoag.org. ABOUT HOAG Hoag is a nonprofit, regional health care delivery network in Orange County, California, that treats more than 30,000 inpatients and 460,000 outpatients annually. Hoag consists of two acute-care hospitals – Hoag Hospital Newport Beach, which opened in 1952, and Hoag Hospital Irvine, which opened in 2010 – in addition to nine health centers and 14 urgent care centers. Hoag has invested $261 million in programs and services to support the underserved community within the past five years, including areas like mental health, homelessness, transportation for seniors, education, and support for single mothers. Hoag is a designated Magnet® hospital by the American Nurses Credentialing Center (ANCC). Hoag offers a comprehensive blend of health care services that includes six institutes providing specialized services in the following areas: cancer, digestive health, heart and vascular, neurosciences, women's health, and orthopedics through Hoag's affiliate, Hoag Orthopedic Institute, which consists of an orthopedic hospital and four ambulatory surgical centers. In the 2021 - 2022 U.S. News & World Report Best Hospitals Rankings, Hoag is the highest ranked hospital in Orange County and the only OC hospital ranked in the Top 10 in California. For an unprecedented 23 years, residents of Orange County have chosen Hoag as one of the county's best hospitals in a local newspaper survey. Visit www.hoag.org for more information. multimedia:https://www.prnewswire.com/news-releases/hoag-first-hospital-in-orange-county-to-enroll-patients-in-nk-cell-therapy-clinical-trial-for-triple-negative-breast-cancer-patients-301400676.html
Hoag长老会纪念医院今天宣布,它已经招募了第一批两名患者参加一项临床研究,评估三阴性乳腺癌妇女的“自然杀手”或NK细胞疗法。Hoag是奥兰治县第一个也是唯一一个在这项研究中招募患者的网站。 Phase1/B2开放标记研究将评估化学免疫疗法与“Trodelvy”(一种低剂量化疗)、与加州卡尔弗城免疫生物公司的Anktiva受体激动剂和NK细胞疗法(一种免疫疗法)结合的安全性和有效性。参与者是三阴性乳腺癌患者,他们至少有两次转移性疾病的治疗经验。治疗将持续长达一年。 细胞疗法包括修改免疫细胞来识别--并杀死--癌症。Hoag参与了各种细胞治疗试验,评估“自然杀伤”或NK细胞治疗,已被证明对治疗实体瘤有益。 Hoag家庭癌症研究所NK细胞治疗研究联合主任、该试验的首席研究员Chaitali Nangia医学博士说:“转移性三阴性乳腺癌患者通常预后不良,癌症复发率高,目前的治疗在不可接受的高毒性水平下反应持续时间短。”“我们正处于使用‘自然杀伤’细胞的这些新组合方法的前沿,这些细胞有可能与其他药物合作,在保持患者生活质量的同时给予持久和深刻的反应。” 根据美国癌症协会的数据,三阴性乳腺癌约占所有乳腺癌的10-15%。三阴性乳腺癌在40岁以下的女性、黑人女性和BRCA1突变者中更常见。三阴性乳腺癌是一种更具侵袭性的乳腺癌,直到最近还缺乏个性化治疗的特定目标。组合化学免疫疗法已经开始填补这些空白,现在是许多针对这些途径的临床试验的支柱。 “Hoag致力于通过探索新药和疗法的安全性和有效性,包括免疫治疗的前景广阔的领域,特别是评估NK细胞在治疗几种挑战性癌症方面的有效性,在推进治疗选择和改善医疗保健方面处于领先地位,”Hoag家庭癌症研究所执行医学主任Grace E.Hoag医学博士伯顿·艾森伯格(Burton Eisenberg)说。 HOAG的临床试验得到了慈善机构的大力支持,慈善机构提供了吸引和支持这些高级试验的基础设施,包括研究护士、数据和试验协调员、变异科学家等。 Hoag家庭癌症研究所为所有实体瘤癌症提供全面的临床试验。欲了解更多信息,请发电子邮件clinicalresearch@hoag.org。 关于HOAG Hoag是加利福尼亚州奥兰治县的一个非营利的地区医疗保健提供网络,每年治疗3万多名住院患者和46万名门诊患者。Hoag由两家急性护理医院组成--1952年开业的新港海滩Hoag医院和2010年开业的欧文Hoag医院--此外还有9家健康中心和14家紧急护理中心。在过去的五年里,Hoag已经在项目和服务上投资了2.61亿美元,以支持服务不足的社区,包括精神健康、无家可归、老年人交通、教育和对单身母亲的支持等领域。Hoag是美国护士认证中心(ANCC)指定的磁铁®医院。Hoag提供综合保健服务,包括六个机构,在以下领域提供专门服务:癌症、消化健康、心脏和血管、神经科学、妇女健康和骨科,通过Hoag的附属机构Hoag骨科研究所,该研究所由一所骨科医院和四个流动外科中心组成。在2021-2022年《美国新闻与世界报道》最佳医院排名中,Hoag是奥兰治县排名最高的医院,也是加州唯一一家排名前10的OC医院。史无前例的23年来,奥兰治县的居民在当地报纸的一项调查中选择Hoag作为该县最好的医院之一。欲了解更多信息,请访问www.hoag.org。 多媒体:https://www.prnewswire.com/news-releases/hoag-first-hospital-in-orange-county-to-regorits-in-nk-cell-therapy-linical-trial-in-nk-breast-cancer-patients-301400676.html